FTDZX Holdings — Franklin Biotechnology Discovery Fund
All 113 reported holdings of Franklin Biotechnology Discovery Fund (FTDZX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Jazz Pharmaceuticals plc | 5.55% | $57.47M |
| Amgen, Inc. | 4.75% | $49.16M |
| Gilead Sciences, Inc. | 4.66% | $48.28M |
| Regeneron Pharmaceuticals, Inc. | 4.16% | $43.14M |
| Vertex Pharmaceuticals, Inc. | 4.02% | $41.64M |
| Argenx SE | 3.69% | $38.27M |
| Franklin Institutional U.S. Government Money Market Fund | 3.05% | $31.63M |
| Franklin Institutional U.S. Government Money Market Fund | 2.96% | $30.71M |
| Ascendis Pharma A/S | 2.87% | $29.76M |
| Insmed, Inc. | 2.82% | $29.22M |
| Revolution Medicines, Inc. | 2.82% | $29.17M |
| Praxis Precision Medicines, Inc. | 2.51% | $25.96M |
| Dianthus Therapeutics, Inc. | 2.29% | $23.78M |
| Guardant Health, Inc. | 2.09% | $21.68M |
| Mirum Pharmaceuticals, Inc. | 2.02% | $20.94M |
| PTC Therapeutics, Inc. | 2.01% | $20.80M |
| AstraZeneca plc | 1.85% | $19.21M |
| Neurocrine Biosciences, Inc. | 1.72% | $17.81M |
| Bridgebio Pharma, Inc. | 1.66% | $17.15M |
| Alnylam Pharmaceuticals, Inc. | 1.62% | $16.76M |
| Abivax SA | 1.60% | $16.56M |
| Spyre Therapeutics, Inc. | 1.58% | $16.38M |
| Ionis Pharmaceuticals, Inc. | 1.48% | $15.36M |
| Oruka Therapeutics, Inc. | 1.47% | $15.21M |
| Mineralys Therapeutics, Inc. | 1.46% | $15.13M |
| EyePoint, Inc. | 1.43% | $14.83M |
| Eli Lilly & Co. | 1.27% | $13.15M |
| CG oncology, Inc. | 1.21% | $12.56M |
| Indivior Pharmaceuticals, Inc. | 1.18% | $12.23M |
| Benitec Biopharma, Inc. | 1.16% | $11.99M |
| Arcutis Biotherapeutics, Inc. | 1.13% | $11.74M |
| Syndax Pharmaceuticals, Inc. | 1.02% | $10.56M |
| Amylyx Pharmaceuticals, Inc. | 1.00% | $10.39M |
| Cytokinetics, Inc. | 0.99% | $10.30M |
| BeOne Medicines Ltd. | 0.95% | $9.87M |
| Tango Therapeutics, Inc. | 0.93% | $9.68M |
| Dyne Therapeutics, Inc. | 0.88% | $9.11M |
| Solid Biosciences, Inc. | 0.88% | $9.10M |
| Bicara Therapeutics, Inc. | 0.81% | $8.36M |
| Vaxcyte, Inc. | 0.80% | $8.34M |
| Alkermes plc | 0.76% | $7.85M |
| Spyre Therapeutics, Inc. | 0.74% | $7.71M |
| BioNTech SE | 0.73% | $7.59M |
| Nuvalent, Inc. | 0.73% | $7.57M |
| Xenon Pharmaceuticals, Inc. | 0.67% | $6.94M |
| Achieve Life Sciences, Inc. | 0.67% | $6.92M |
| Apogee Therapeutics, Inc. | 0.66% | $6.86M |
| ORIC Pharmaceuticals, Inc. | 0.63% | $6.51M |
| Oruka Therapeutics, Inc. | 0.62% | $6.43M |
| Alto Neuroscience, Inc. | 0.59% | $6.16M |
| Olema Pharmaceuticals, Inc. | 0.53% | $5.47M |
| Phathom Pharmaceuticals, Inc. | 0.53% | $5.45M |
| Aura Biosciences, Inc. | 0.52% | $5.40M |
| Newamsterdam Pharma Co. NV | 0.52% | $5.36M |
| VeraDermics, Inc. | 0.52% | $5.34M |
| Inventiva SACA | 0.48% | $4.97M |
| Contineum Therapeutics, Inc. | 0.47% | $4.89M |
| Palisade Bio, Inc. | 0.41% | $4.24M |
| Alto Neuroscience, Inc. | 0.41% | $4.24M |
| Structure Therapeutics, Inc. | 0.41% | $4.22M |
| Thermo Fisher Scientific, Inc. | 0.40% | $4.11M |
| Contineum Therapeutics, Inc. | 0.37% | $3.78M |
| Benitec Biopharma, Inc. | 0.36% | $3.75M |
| Obsidian Therapeutics, Inc. | 0.35% | $3.67M |
| Kailera Therapeutics, Inc. | 0.35% | $3.66M |
| enGene Therapeutics, Inc. | 0.34% | $3.54M |
| uniQure NV | 0.34% | $3.49M |
| Ray Therapeutics, Inc. | 0.33% | $3.40M |
| Sensei Biotherapeutics, Inc. | 0.32% | $3.36M |
| Jade Biosciences, Inc. | 0.32% | $3.36M |
| Context Therapeutics, Inc. | 0.32% | $3.30M |
| Immix Biopharma, Inc. | 0.31% | $3.19M |
| Candid Therapeutics, Inc. | 0.29% | $3.05M |
| Lycia LLC | 0.29% | $3.02M |
| Relay Therapeutics, Inc. | 0.29% | $3.02M |
| Achieve Life Sciences, Inc. | 0.29% | $2.98M |
| Palisade Bio, Inc. | 0.28% | $2.89M |
| Ultragenyx Pharmaceutical, Inc. | 0.26% | $2.67M |
| GRAIL, Inc. | 0.24% | $2.53M |
| SpyGlass Pharma, Inc. | 0.24% | $2.51M |
| Ideaya Biosciences, Inc. | 0.23% | $2.38M |
| Candid, Inc. | 0.23% | $2.37M |
| Sionna Therapeutics, Inc. | 0.23% | $2.36M |
| Sartorius AG | 0.23% | $2.35M |
| Verastem, Inc. | 0.21% | $2.19M |
| Artiva Biotherapeutics, Inc. | 0.19% | $1.97M |
| Acumen Pharmaceuticals, Inc. | 0.19% | $1.98M |
| Satellos Bioscience, Inc. | 0.19% | $1.96M |
| Sartorius Stedim Biotech | 0.18% | $1.87M |
| Zentalis Pharmaceuticals, Inc. | 0.17% | $1.76M |
| Adicet Bio, Inc. | 0.16% | $1.70M |
| LENZ Therapeutics, Inc. | 0.16% | $1.68M |
| JATT II Acquisition Corp. | 0.15% | $1.54M |
| BioAge Labs, Inc. | 0.15% | $1.53M |
| Avalo Therapeutics, Inc. | 0.14% | $1.50M |
| Structure Therapeutics, Inc. | 0.14% | $1.44M |
| Vicore Pharma Holding AB | 0.14% | $1.41M |
| Sensei Biotherapeutics, Inc. | 0.13% | $1.30M |
| Achieve Life Sciences, Inc. | 0.12% | $1.24M |
| Eikon Therapeutics, Inc. | 0.12% | $1.22M |
| Satellos Bioscience, Inc. | 0.07% | $766.31K |
| Cardiff Oncology, Inc. | 0.07% | $759.40K |
| Achieve Life Sciences, Inc. | 0.06% | $621.85K |
| Carmot Therapeutics, Inc. | 0.05% | $534.29K |
| Acumen Pharmaceuticals, Inc. | 0.05% | $533.70K |
| IN8bio, Inc. | 0.05% | $488.16K |
| Neumora Therapeutics, Inc. | 0.04% | $461.85K |
| Assembly Biosciences, Inc. | 0.04% | $451.06K |
| ARS Pharmaceuticals, Inc. | 0.02% | $228.65K |
| Assembly Biosciences, Inc. | 0.00% | $28.19K |
| IN8bio, Inc. | 0.00% | $5.66K |
| Danish Krone | 0.00% | $116 |
| Sanofi SA | 0.00% | $0 |
FTDZX overview: performance, fees, allocation and SEC filings